PT3221349T - Anticorpos tau humanizados na doença de alzheimer - Google Patents

Anticorpos tau humanizados na doença de alzheimer

Info

Publication number
PT3221349T
PT3221349T PT158372110T PT15837211T PT3221349T PT 3221349 T PT3221349 T PT 3221349T PT 158372110 T PT158372110 T PT 158372110T PT 15837211 T PT15837211 T PT 15837211T PT 3221349 T PT3221349 T PT 3221349T
Authority
PT
Portugal
Prior art keywords
alzheimer
disease
tau antibodies
humanized tau
humanized
Prior art date
Application number
PT158372110T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of PT3221349T publication Critical patent/PT3221349T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
PT158372110T 2014-11-19 2015-11-18 Anticorpos tau humanizados na doença de alzheimer PT3221349T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462081809P 2014-11-19 2014-11-19

Publications (1)

Publication Number Publication Date
PT3221349T true PT3221349T (pt) 2021-01-21

Family

ID=55411706

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158372110T PT3221349T (pt) 2014-11-19 2015-11-18 Anticorpos tau humanizados na doença de alzheimer

Country Status (24)

Country Link
US (3) US10160799B2 (enExample)
EP (2) EP3786182A1 (enExample)
JP (3) JP6830061B2 (enExample)
KR (1) KR20170126855A (enExample)
CN (1) CN107428820B (enExample)
AU (2) AU2015348012B2 (enExample)
BR (1) BR112017010498A2 (enExample)
CA (1) CA2966964A1 (enExample)
CY (1) CY1123746T1 (enExample)
DK (1) DK3221349T3 (enExample)
ES (1) ES2848376T3 (enExample)
HR (1) HRP20210124T1 (enExample)
HU (1) HUE053239T2 (enExample)
IL (2) IL251921B (enExample)
LT (1) LT3221349T (enExample)
MX (2) MX388142B (enExample)
PL (1) PL3221349T3 (enExample)
PT (1) PT3221349T (enExample)
RS (1) RS61431B1 (enExample)
RU (2) RU2730668C2 (enExample)
SG (1) SG11201703237VA (enExample)
SI (1) SI3221349T1 (enExample)
SM (1) SMT202100055T1 (enExample)
WO (1) WO2016079597A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
WO2016073693A2 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
ES2848376T3 (es) * 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
EA201892417A1 (ru) * 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
AU2017259039B2 (en) 2016-05-02 2024-05-09 Prothena Biosciences Limited Antibodies recognizing tau
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
CN110418804A (zh) * 2017-03-28 2019-11-05 扬森疫苗与预防公司 与tau特异性地结合的结合分子
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
WO2019048017A1 (en) * 2017-09-07 2019-03-14 Danmarks Tekniske Universitet METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND
PE20210115A1 (es) 2017-10-16 2021-01-19 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
CA3095443A1 (en) * 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
CN112166117A (zh) * 2018-05-03 2021-01-01 华盛顿大学 基于位点特异性tau磷酸化的诊断和治疗方法
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
WO2020077380A1 (en) * 2018-10-17 2020-04-23 The University Of Queensland Methods and compositions for treating tauopathies
KR20210090184A (ko) * 2018-11-08 2021-07-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7630834B2 (ja) * 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN114555631A (zh) * 2019-08-13 2022-05-27 华盛顿大学 检测MTBR tau同种型的方法及其用途
CN114340654A (zh) 2019-09-09 2022-04-12 阿克松神经系统科学公司 阿尔茨海默病和轻度认知障碍的生物标志物和治疗
BR112022004326A2 (pt) 2019-09-10 2022-08-23 Univ Washington Ensaio de base sanguínea para diagnóstico e tratamento com base em fosforilação de tau específica do sítio
BR112022011337A2 (pt) * 2019-12-12 2022-08-23 Alector Llc Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
US20230201136A1 (en) * 2020-02-28 2023-06-29 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CA3192987A1 (en) * 2020-09-22 2022-03-31 Kathleen E. Clarence-Smith Pharmaceutical combination for the treatment of human hypocholinergic disorders
CN113156134B (zh) * 2020-11-26 2024-01-23 江苏荃信生物医药股份有限公司 用于检测人白介素23的elisa试剂盒及检测方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250044781A (ko) * 2022-08-10 2025-04-01 주식회사 엔케이맥스 확장된 자연 살해 세포를 이용한 알츠하이머병 치료 방법
EP4587470A1 (en) 2022-09-15 2025-07-23 Voyager Therapeutics, Inc. Tau binding compounds
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech Inc New uses of omalizumab
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JPH07509250A (ja) 1992-07-27 1995-10-12 アメリカ合衆国 血液脳バリヤーへのリポソームの標的化
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2142190C (fr) 1995-02-14 1998-01-27 Marc Lessard Conduite d'exfiltration d'air use
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
WO1997023243A1 (en) 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Branched hydrazone linkers
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1214598B1 (en) 1999-09-09 2006-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening for inhibitors of "paired helical filaments"
EP3150633A1 (en) 2000-02-24 2017-04-05 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2004007547A2 (en) 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Truncated tau proteins
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
CN100386068C (zh) 2002-12-03 2008-05-07 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
CA2511606A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
SI2625198T1 (sl) * 2010-10-07 2015-11-30 Ac Immune S.A. Epfl Innovation Park Protitelesa, ki prepoznavajo fosfo-tau
CA2813493C (en) * 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
EP2758433B1 (en) 2011-09-19 2017-10-18 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
PT2935326T (pt) * 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
ES2848376T3 (es) * 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer

Also Published As

Publication number Publication date
CN107428820A (zh) 2017-12-01
IL251921B (en) 2021-07-29
WO2016079597A1 (en) 2016-05-26
HK1244495A1 (en) 2018-08-10
EP3221349A1 (en) 2017-09-27
JP6864763B2 (ja) 2021-04-28
US20190169276A1 (en) 2019-06-06
IL284250A (en) 2021-07-29
RU2730668C2 (ru) 2020-08-24
MX2017006663A (es) 2017-08-21
JP2020141669A (ja) 2020-09-10
HRP20210124T1 (hr) 2021-03-19
DK3221349T3 (da) 2021-01-04
SG11201703237VA (en) 2017-06-29
CA2966964A1 (en) 2016-05-26
US20180142007A1 (en) 2018-05-24
JP6830061B2 (ja) 2021-02-17
US11319363B2 (en) 2022-05-03
RU2017120688A3 (enExample) 2019-07-17
US10745469B2 (en) 2020-08-18
US10160799B2 (en) 2018-12-25
MX388142B (es) 2025-03-19
PL3221349T3 (pl) 2021-05-17
CN107428820B (zh) 2022-03-22
RU2017120688A (ru) 2018-12-19
SMT202100055T1 (it) 2021-03-15
CY1123746T1 (el) 2022-05-27
EP3221349B1 (en) 2020-11-04
AU2015348012A1 (en) 2017-05-18
MX2021014367A (es) 2022-01-06
RS61431B1 (sr) 2021-03-31
AU2020227007B2 (en) 2024-05-30
US20210009666A1 (en) 2021-01-14
RU2020126237A (ru) 2020-12-01
WO2016079597A8 (en) 2020-07-02
HUE053239T2 (hu) 2021-06-28
SI3221349T1 (sl) 2021-02-26
KR20170126855A (ko) 2017-11-20
AU2015348012B2 (en) 2020-07-02
AU2020227007A1 (en) 2020-09-17
JP2018502558A (ja) 2018-02-01
EP3786182A1 (en) 2021-03-03
BR112017010498A2 (pt) 2017-12-26
LT3221349T (lt) 2021-02-10
ES2848376T3 (es) 2021-08-09
JP2021119774A (ja) 2021-08-19
IL251921A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL284250A (en) Tau antibodies of human origin in Alzheimer's disease
IL285722A (en) Methods for treating Alzheimer's disease
ZA201900373B (en) Anti-tim-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL252929B (en) Anti-acth antibodies from humans and their use
GB201610044D0 (en) Antibodies
IL251837A0 (en) Anti-endoglin antibodies and their uses
PL3311171T3 (pl) Epitop przeciwciała
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201616699D0 (en) Antibodies
PT3101132T (pt) Anticorpo humano anti-transtirretina
GB201603291D0 (en) Antibodies
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
IL267271A (en) Antibodies against il-5
PT3484921T (pt) Anticorpos anti-il-22r
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
IL260083B1 (en) Antibody against myl9
SG11201703292VA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201414038D0 (en) Alzheimer's disease
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies